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Abstract
Background—Persons with inflammatory bowel disease (IBD) have an increased risk of venous 
thromboembolism (VTE). We sought to examine whether self-report of hormonal contraception 
(HC), as a proxy for exposure to estrogen-based contraception, was less common for women with 
multiple risk factors for VTE.
Methods—We examined the prevalence of personal use of hormonal birth control in a large 
internet-based cohort of patients with IBD. To determine whether HC was less common among 
IBD patients with increased risk of thrombosis, we estimated unadjusted and adjusted prevalence 
ratios (PR and aPR) for use of HC.
Results—1,499 female survey respondents answered optional fertility questions and were 
included in the analysis. The prevalence of HC was 33.7% (95% CI 30.6 – 36.9%) among women 
with Crohn’s disease and was 32.6% (95% CI 28.6 – 36.8%) for women with ulcerative colitis. 
Women with one risk factor for thrombosis were not significantly less likely to receive hormonal 
contraception (PR = 0.91, 95% CI 0.76 – 1.08; aPR = 0.94, 95% CI 0.80 – 1.11) compared to 
women without risk factors, nor were women with two or more risk factors (PR = 1.10, 95% CI 
0.56 – 1.28; aPR = 1.10, 95% CI 0.83 – 1.45). Use of an intrauterine device was also similar 
between women with and without risk factors for VTE.
Conclusion—The prevalence of HC use in women with multiple risk factors was similar to that 
in women without risk factors, which represents an opportunity for prevention. Gastroenterologists 
should ask IBD patients using HC about risk factors for thromboembolic disease to identify 
patients who may benefit from alternative contraception.
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Background
The inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease (CD), 
are characterized by chronic remitting and relapsing bowel inflammation.1 The choice of 
contraceptive methods in patients with IBD is more complex because of an increased 
thromboembolic risk with use of oral contraceptives containing estrogen in IBD along with 
the elevated baseline risk of venous thromboembolism (VTE) in IBD.2, 3 Though IBD 
diagnosis is not an absolute contraindication to estrogen-based contraception, patients with 
active disease or additional risk factors may benefit from alternative methods of 
contraception.
The prevalence of estrogen-based contraception use among patients with IBD has been 
reported to range from 39% to 51%17–20 Despite the widespread use of these medications, 
the well-described risks of VTE are rarely addressed by gastroenterologists during clinic 
visits with IBD patients.21 Alternatives to estrogen-based contraception exist. Several forms 
of IUD are marketed in the United States and are well tolerated, highly effective, and not 
associated with increased risk for thrombosis.22, 23 Progesterone-only contraceptive pills, 
implants, and injectables also avoid exposure to exogenous estrogen.24
IBD diagnosis is a moderate risk factor for VTE with a risk ratio of 1.96 in a recent meta-
analysis.4 The absolute rate of VTE in population studies of patients with IBD is estimated 
at 0.1 – 0.5% per year.5–10 Among patients with IBD, active disease has been reported as a 
strong risk factor for deep vein thrombosis (rate ratio 6.4).25 The effect of VTE risk factors 
among patients with IBD is unknown, and care should be taken in generalizing studies of the 
general population to patients with IBD. New users of corticosteroids in the general 
population may have as much as a threefold increase in risk for VTE.11 Obesity is a dose-
dependent risk factor for VTE with an estimated hazard ratio of 1.07 per standard deviation 
or 2.14 for obese versus normal weight women.12, 13 Current smoking confers a relatively 
small increase in risk for VTE, with a relative risk of 1.23 in a recent meta-analysis.26 Age is 
also a strong risk factor for VTE. While patients of 30 years of age have an estimated 
incidence rate less than 0.1% per years, those over 80 years of age have an estimated rate 
over 1%.14 Other important risk factors include long-haul travel, the metabolic syndrome, 
and air pollution,15 but these data were not available in the present study.
We used The Crohn’s and Colitis Foundation of America (CCFA) Partners Cohort of 
patients with IBD to study exposure to estrogen-based contraception, using hormonal 
contraception (HC) as a proxy. This large, Internet cohort provides statistical precision to 
examine the association of risk factors for VTE with the choice of contraceptive. We sought 
to describe the prevalence of various methods of contraception among women with IBD, and 
to examine whether the use of HC was limited or the use of IUD was increased among 
women with multiple risk factors for thromboembolism.
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Materials and Methods
The Crohn’s and Colitis Foundation of America (CCFA) Partners Cohort
CCFA Partners is an Internet-based cohort of patients with inflammatory bowel diseases.27 
Patients were recruited through Crohn’s and Colitis Foundation of America (CCFA) email 
rosters, chapter events, and promotional activities beginning in June 2012.28 Patients age 18 
or older with self-reported IBD were eligible. Web forms incorporated logic and range 
checks to minimize missing or erroneous data in real time. Respondents were queried about 
demographic information, disease phenotype, medication use, and health-related behaviors. 
An optional module included questions about contraception, menstrual and pregnancy 
history, and gestational outcomes. The Institutional Review Board at the University of North 
Carolina at Chapel Hill approved the study protocol.
We included patients for analysis with CD or UC who answered the optional fertility module 
of the baseline CCFA Partners survey. Patients with indeterminate colitis were excluded. 
Patients who reported not being sexually active or currently trying to conceive, and women 
who had undergone menopause or were pregnant or breastfeeding women were excluded. 
Women over age 60 were excluded regardless of whether they reported menopause. Within 
the surveys, patients who endorsed using any method of birth control with their current 
sexual partner were presented a follow-up question in which they could select one or more 
of the following birth control methods: no sexual relations that could result in pregnancy, 
barrier methods, IUD, hormonal contraception, rhythm or natural family planning, 
sterilization operation, and withdrawal.
Statistical Methods
We performed descriptive statistics, stratified by IBD subtype, including number and percent 
for categorical variables. The prevalence and method of birth control use was tabulated for 
all included subjects. We constructed 95% profile likelihood binomial confidence intervals 
(CI) around point estimates of prevalence over zero, and exact intervals around point 
estimates of prevalence of zero.29, 30
We used generalized linear models with targeted maximum likelihood estimation to estimate 
unadjusted and adjusted prevalence ratios (PR) for hormonal birth control use depending on 
known risk factors for thromboembolism.31 Risk factors were chosen from established 
clinical risk factors for VTE that were available to the present study, including current 
smoking, current use of corticosteroids, and obesity.15 We also examined the effects of 
having active IBD; defined as simple clinical colitis activity index >2 or short Crohn’s 
disease activity index>150.32, 33 We chose adjustment sets to limit open confounding paths 
based on examination of directed acyclic graphs. These factors included age, current 
smoking, IBD type, any history of surgery, and any history of hospitalization. Potential 
confounders were parameterized using flexible trend analysis and comparison of nested 
models based on Akaike information criterion corrected (AICc) to minimize residual 
confounding. Age was parameterized as a restricted quadratic spline with internal knots at 
25, 35, and 45 years. Because the outcome was much less common than the exposure, 
inverse probability of treatment weighting was used to control confounding in analysis of 
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IUD use.34 The exposure model was constructed using similar criteria to the hormonal 
contraception analysis, including flexible trend analysis and comparison of nested models on 
AICc.
We performed a sensitivity analysis to examine the effect of outcome misclassification given 
that some patients with IBD endorsing hormonal contraception use were likely using 
progesterone-only methods. In random imputation analyses, a proportion of patients with 
hormonal contraception use were imputed to non-use both randomly and assuming an 
association with exposure to risk factors. For this sensitivity analysis, bootstrap 95% 
confidence limits were calculated using 500 samples per estimate. Statistical analyses were 
performed in R 3.2.2.35
Results
Of 3,402 women responding to the CCFA Partners baseline survey, 1,538 answered the 
fertility questions and 1,340 who were at risk for using contraception were included for 
analysis. The analytic cohort was young, predominantly Caucasian, and well educated (table 
1). Most patients received GI specialist care in a private center (table 2). Use of birth control 
was common among women in all age groups (table 3). Hormonal contraception was the 
most common method among 18 to 34 year olds, a group that also frequently used barrier 
methods (figure 1). Surgical sterilization was more common in older age groups. Overall a 
large proportion of women with IBD were exposed to hormonal contraception. The 
prevalence among women with CD was 33.7% (95% CI 30.5 – 36.9%) and with UC was 
32.6% (95% CI 28.6 – 36.8%). IUD use was much less common with prevalence of 6.3% 
(95% CI 4.8 – 8.1%) among CD patients and 7.0% (95% CI 5.0 – 9.4%) among UC patients.
Female patients with IBD who had multiple risk factors for thromboembolism had similar 
overall prevalence of HC use to women with no risk factors (table 4). Patients who were 
underweight (adjusted PR = 0.62, 95% CI 0.45 – 0.86), overweight (adjusted PR = 0.81, 
95% CI 0.67 – 0.97), or obese (adjusted PR = 0.88, 95% CI 0.73 – 1.05) had lower 
prevalence of exposure to hormonal contraception compared to women of normal weight. 
The negative associations with overweight and obesity were attenuated by adjustment, 
whereas the negative association with underweight was strengthened by adjustment. 
Exposure to hormonal contraception use did not significantly differ between women 
receiving GI care in private versus academic settings (adjusted PR = 1.05, 95% CI 0.83 – 
1.33). Compared to women with no risk factors for thrombosis, women with one risk factor 
for thrombosis were not significantly less likely to receive hormonal contraception 
(unadjusted PR = 0.91, 95% CI 0.76 – 1.08; adjusted PR = 0.94, 95% CI 0.76 – 1.08), nor 
were women with two or more risk factors (unadjusted PR = 1.10, 95% CI 0.56 – 1.28; 
adjusted PR = 1.10, 95% CI 0.83 – 1.45). In a sensitivity analysis examining the effect of 
outcome misclassification, estimates of the unadjusted PR for one or multiple risk factors for 
VTE were reduced if use of non-estrogen hormonal contraception was strongly associated 
with risk factors (table S-1). In the analysis assuming the strongest potential for bias (15% of 
women using non-estrogen hormonal contracetption and those with any VTE risk factors 
being twice as likely to use the non-estrogen hormonal contraception), the estimated 
prevalence of estrogen-containing contraception was estimated to be 31%–34% lower than 
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for women without VTE risk factors. Women with one or more risk factors for thrombosis 
were not significantly more likely to receive an IUD (unstandardized PR = 0.98, 95% CI 
0.95 – 1.01; standardized PR = 0.99, 95% CI 0.95 – 1.03; figure 2).
Discussion
In women with IBD who belong to a large Internet cohort, the use of hormonal 
contraception was widespread (CD prevalence = 33.7, UC prevalence = 32.6%). We did not 
find evidence that hormonal contraception use was less common among women with risk 
factors for thrombosis. To the contrary, point estimates of the prevalence ratio were close to 
the null. The absence of such a finding in spite of good statistical precision speaks to an 
opportunity for prevention because rates of thromboembolism are elevated among patients 
with IBD compared to the general population. Practice guidelines suggest that hormonal 
contraception containing estrogen should be avoided even in healthy patients with multiple 
risk factors for thrombosis or atherosclerotic disease.36–38 There was similar absence of 
evidence that IUD use was more common among women with risk factors for thrombosis.
The burden of thromboembolic disease among patients with IBD is substantial, with a recent 
meta-analysis reporting a risk ratio of 1.96 compared to the general population.4 Reports of 
the rate of deep vein thrombosis in population-based studies suggest an incidence rate of 1–5 
per 1,000 person-years.5–10 Beyond the concern for venous thromboembolism in general, 
mesenteric vein thrombosis is increasingly recognized as clinically significant among 
patients with IBD, particularly those with a history of surgery.39, 40 Patients with IBD 
experience venous thromboembolism at a younger age and with greater mortality than the 
general population.41, 42
Our findings are generally consistent with the prior literature in that women with IBD in this 
study used contraception at a higher rate than in the general population.43 In a study with 
mean age of 28 years, the reported rate was 40.5%.17 In a study with mean age of 32 years, 
the rate of oral contraception use was 51%.44 A study set in Cape Town, South Africa, 
reported a rate of 38.6% at a mean age of 31 year, but comparison may be limited by cultural 
differences.20 These studies of IBD patients reported much higher usage than in the National 
Survey of Family Growth (NSFG), which reported 22.2% use among women 15 to 24, 
16.9% among women 25 to 34, and 9.7% among women 35 to 44 years of age.45 Studies 
have suggested these differences could reflect the desire for “voluntary childlessness” 
among patients with IBD, but direct comparisons to national data are problematic because 
study populations with IBD differ from the general population in demographic and other 
characteristics.
Women in the present study, with recruitment from June 2012 to the present day, were more 
likely to use IUD’s than in the NSFG from 2011 to 2013. This difference may reflect the 
young, highly educated women in the present study. This may also represent progress toward 
lower risk or more effective contraceptives among this population. Further studies of the 
costs, risks, and benefits of contraception in patients with IBD are warranted given the 
prevalence of this exposure and the potential to avert serious adverse events in the high-risk 
population of IBD patients.
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Patients and clinicians face multiple challenges in the choice of family planning strategy in 
IBD. There is some evidence that HC can increase the risk of relapse among women already 
diagnosed with CD, although the data are conflicting.17, 18, 46 HC may alleviate symptoms 
related to the menstrual cycle in some women with IBD.47 Despite this, patients with two or 
more risk factors for thromboembolism in addition to IBD would need significant benefits 
from estrogen-based as compared to other methods to justify the increased risk for 
thrombosis. Although it is unlikely physicians treating IBD would place an IUD themselves, 
they have an important role in referring patients with multiple risk factors for IBD to a 
physician with expertise in contraception who could place an IUD or chose a satisfactory 
alternative method.
The study has several important strengths. The large sample size allows for statistically 
precise estimation of the prevalence of birth control methods across age, IBD type, and 
gender. Minimal missing data reduce the possibility of bias from systematic missing data. 
The Internet cohort design provides a large sample size with less missing data than postal 
methods.48, 49 This study also has several limitations. As with any survey there is a potential 
for selection bias. This cohort likely represents a better educated, English speaking, and 
younger population of Internet users as compared with the general population.50, 51 Our 
analysis of the number of additional risk factors among patients with IBD assumes the 
impact of each risk factor on decision-making is equal and additive. This doesn’t capture the 
complex reality of clinical decision making or reflect the varying magnitude of risk factors. 
Nonetheless, this imperfect model has utility to show that clinicians and patients in general 
don’t seem to avoid estrogen-based contraception to the degree that might be expected in 
patients with risk factors for VTE.
A further limitation is that we did not ask about the use of specific hormonal contraceptives. 
Hormonal contraceptives vary in their thromboembolic risk depending primarily on estrogen 
content.52, 53 Progesterone-only contraceptives are likely neutral with respect to 
thromboembolism, with a recent meta-analysis reporting a combined risk ratio of 1.03 (95% 
CI 0.76 – 1.39).24 For combined oral contraceptives, the meta-analytic risk ratio for VTE 
varies widely ranging from 1.33 (95% CI 1.08 – 1.63) in one meta-analysis to 3.5 (95% CI 
2.9 – 4.3) in another.54–57 We evaluated the potential for bias due to imperfect ascertainment 
of exposure to estrogen-based contraception. Use of progesterone-only contraceptive pills is 
uncommon at 0.4%, but progesterone-only implants or patches accounted for 4.2% of NSFG 
respondents and Depo-Provera accounted for 10.6%.58, 59 This suggests outcome 
misclassification could be as high as 15%. However, even with our most extreme 
hypothetical sensitivity assumptions, our data suggest that the use of estrogen-containing 
contraception is common in IBD patients with VTE risk factors. The similar prevalence of 
IUD use between those with VTE risk factors and those without further supports our 
primary findings that there is very little avoidance of estrogen-containing hormonal 
contraception in IBD patients.
In summary, women in an Internet cohort of subjects with IBD reported using hormonal 
contraception, a proxy for estrogen-based contraception, at rates greater than the general 
population. Use of HC among women with IBD was not limited in subjects with multiple 
additional risk factors for thrombosis. Though IBD diagnosis is not an absolute 
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contraindication to estrogen-based contraception, patients with active disease or additional 
risk factors may benefit from alternative methods of contraception. Gastroenterologists and 
primary care providers should counsel patients with IBD on the risk of thrombosis 
associated with HC use and make an informed decision based on patients’ risk factors and 
preferences.
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Figure 1. 
Trends in Birth Control Methods by Age of Respondent among 1,340 Women with 
Ulcerative Colitis or Crohn’s Disease among Patients at Risk for Using Contraception.
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Figure 2. 
Distribution of Propensity Scores by the Exposure, Having One or More Risk Factors for 
Deep Vein Thrombosis, Compared to No Risk Factors.
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